专利检索 ap:("David WITTER" OR "Shuhei KAWAMURA" OR "Michelle MACHACEK" OR "Ryan QUIROZ" OR "Michael H. REUTERSHAN" OR "Sebastian SCHNEIDER" OR "Phieng SILIPHAIVANH" OR "Yingchun YE" OR "Charles S. YEUNG" OR "Merck Sharp & Dohme Corp.") AND inv:"Ryan Quiroz" 第 1 页

1.

发明申请
PRMT5 INHIBITORS 有权

公开(公告)号：US20210277009A1

公开(公告)日：2021-09-09

申请号：US17266474

申请日：2019-08-05

申请人： David WITTER , Shuhei KAWAMURA , Michelle MACHACEK , Ryan QUIROZ , Michael H. REUTERSHAN , Sebastian SCHNEIDER , Phieng SILIPHAIVANH , Yingchun YE , Charles S. YEUNG , Merck Sharp & Dohme Corp.

发明人： David Witter , Shuhei Kawamura , Michelle Machacek , Ryan Quiroz , Michael H. Reutershan , Sebastian Schneider , Phieng Siliphaivanh , Yingchun Ye , Charles S. Yeung

IPC分类号： C07D487/04 , C07D519/00

摘要： The present invention provides a compound of Formula (I) Formula (I) or the pharmaceutically acceptable salts thereof, which are PRMT5 inhibitors.

2.

发明授权
PRMT5 inhibitors 有权

公开(公告)号：US11993602B2

公开(公告)日：2024-05-28

申请号：US17266474

申请日：2019-08-05

申请人： Merck Sharp & Dohme LLC , David Witter , Shuhei Kawamura , Michelle Machacek , Ryan Quiroz , Michael H. Reutershan , Sebastian Schneider , Phieng Siliphaivanh , Yingchun Ye , Charles S. Yeung

发明人： David Witter , Shuhei Kawamura , Michelle Machacek , Ryan Quiroz , Michael H. Reutershan , Sebastian Schneider , Phieng Siliphaivanh , Yingchun Ye , Charles S. Yeung

IPC分类号： C07D487/04 , C07D519/00

CPC分类号： C07D487/04 , C07D519/00

摘要： The present invention provides a compound of Formula (I) Formula (I) or the pharmaceutically acceptable salts thereof, which are PRMT5 inhibitors.

3.

发明申请
PRMT5 INHIBITORS 有权

公开(公告)号：US20220363707A1

公开(公告)日：2022-11-17

申请号：US17266521

申请日：2019-08-05

申请人： Merck Sharp & Dohme Corp. , MSD International GmbH

发明人： Michelle Machacek , David Witter , Craig Gibeau , Chunhui Huang , Shuhei Kawamura , David L. Sloman , Phieng Siliphaivanh , Ryan Quiroz , Murray Wan , Sebastian Schneider , Charles S. Yeung , Michael H. Reutershan , Timothy J. Henderson , Jean-Laurent Paparin , Houcine Rahali , Jonathan M. E. Hughes , Sulagna Sanyal , Yingchun Ye , David A. Candito , Patrick S. Fier , Steven M. Silverman

IPC分类号： C07H19/14 , C07D487/04 , A61P35/00

摘要： The present invention provides a compound of Formula (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.